Cite
Galot R, Le Tourneau C, Saada-Bouzid E, et al. A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. Eur J Cancer. 2021;158:17-26doi: 10.1016/j.ejca.2021.09.003.
Galot, R., Le Tourneau, C., Saada-Bouzid, E., Daste, A., Even, C., Debruyne, P., Henry, S., Zanetta, S., Rutten, A., Licitra, L., Canon, J. L., Kaminsky, M. C., Specenier, P., Rottey, S., Guigay, J., Kong, A., Tinhofer, I., Borcoman, E., Dirix, L., Raveloarivahy, T., Fortpied, C., Vanlancker, M., Morfouace, M., Govaerts, A. S., & Machiels, J. P. (2021). A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. European journal of cancer (Oxford, England : 1990), 15817-26. https://doi.org/10.1016/j.ejca.2021.09.003
Galot, Rachel, et al. "A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial." European journal of cancer (Oxford, England : 1990) vol. 158 (2021): 17-26. doi: https://doi.org/10.1016/j.ejca.2021.09.003
Galot R, Le Tourneau C, Saada-Bouzid E, Daste A, Even C, Debruyne P, Henry S, Zanetta S, Rutten A, Licitra L, Canon JL, Kaminsky MC, Specenier P, Rottey S, Guigay J, Kong A, Tinhofer I, Borcoman E, Dirix L, Raveloarivahy T, Fortpied C, Vanlancker M, Morfouace M, Govaerts AS, Machiels JP. A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. Eur J Cancer. 2021 Oct 09;158:17-26. doi: 10.1016/j.ejca.2021.09.003. Epub 2021 Oct 09. PMID: 34638090.
Copy
Download .nbib